Potential for afatinib as an optimal treatment for advanced non-small cell lung carcinoma in patients with uncommon EGFR mutations-Reference-Cited by-同舟云学术

Potential for afatinib as an optimal treatment for advanced non-small cell lung carcinoma in patients with uncommon EGFR mutations

Published:2019-01 Issue: Volume:127 Page:169-171
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Tanaka Ichidai,Morise Masahiro,Kodama Yuta,Matsui Akira,Ozawa Naoya,Ozone Sachiko,Goto Daiki,Miyazawa Ayako,Hase Tetsunari,Hashimoto Naozumi,Sato Mitsuo^ORCID,Hasegawa Yoshinori

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference10 articles.

1. Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer;Wu;Clin. Cancer Res.,2011

2. Distinct epidemiology and clinical consequence of classic versus rare EGFR mutations in lung adenocarcinoma;Lohinai;J. Thorac. Oncol.,2015

3. Uncommon mutations in epidermal growth factor receptor and response to first and second generation tyrosine kinase inhibitors: a case series and literature review;Galli;Lung Cancer,2018

4. The impact of clinical parameters on progression-free survival of non-small cell lung cancer patients harboring EGFR-mutations receiving first-line EGFR-tyrosine kinase inhibitors;Chen;Lung Cancer,2016

5. Examining treatment outcomes with erlotinib in patients with advanced non-small cell lung cancer whose tumors harbor uncommon EGFR mutations;Klughammer;J. Thorac. Oncol.,2016

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Femoral bone metastasis is a poor prognostic factor in osimertinib-treated patients with EGFR-mutated non-small cell lung cancer: a retrospective, multicenter study;2024-02-15

2. Therapeutic role of EGFR - Tyrosine kinase inhibitors in non-small cell lung cancer with leptomeningeal metastasis;Translational Oncology;2024-01

3. Femoral bone metastasis is a poor prognostic factor in osimertinib-treated patients with EGFR-mutated non-small cell lung cancer;2023-09-15

4. Inconsistent clinical outcomes following afatinib treatment in NSCLC patients harboring uncommon epidermal growth factor receptor mutation;Frontiers in Oncology;2022-11-08

5. Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis;BMC Cancer;2022-06-14